Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases
Abstract
:1. The Status Quo: Current Day Use of Nano Carriers in Drug Delivery
2. The Problem: Limitations of Synthetic Nanocarriers
3. Erythrocyte-Based Carriers Have Advantages (If They Work)
4. Implications for Immunology
5. Erythrocte-Based Virus-like Particles
6. Erythrocyte Liposomes for the Targeted Delivery of Antibiotics
7. Current Limitations and Future Perspective
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
Abbreviations
RES | Reticuloendothelial System |
PEG | Polyethylene Glycol |
RBC | Red Blood Cell |
TM | Thrombomodulin |
E. coli | Escherichia coli |
ASNase | L-asparaginase II |
RBCcm | Cytoplasmic RBC Membrane |
PL | Glycerophospholipid |
SM | Sphingomyelin |
PC | Phosphatidylcholine |
PE | Phosphatidylethanolamine |
PS | Phosphatidylserine |
PG | Phosphatidylglycerol |
PA | Phosphatidic Acid |
PI | Phosphatidylinositol |
MPS | Mononuclear Phagocyte System |
SARS-CoV-2 | Severe Acute Respiratory Syndrome—Coronavirus-2 |
APC | Antigen Presenting Cell |
VLD | Virus Like Particle |
SEC | Size Exclusion Chromatography |
ACE-2 | Angiotensin Converting Enzyme 2 |
RBD | Receptor Binding Domain |
TMD | Transmembrane Binding Domain |
MD | Molecular Dynamics |
TEM | Transmission Electron Microscopy |
TR-DHPE | Texas Red 1,2-Dihexadecanoyl-sn-glycero-3-phosphoethanolamine |
AF488 | Alexa Fluor 488 |
DMPS | Dimyristoyl-sn-glycero-3-phospho-L-serine |
PmB | Polymyxin B |
GFP | Green Fluorescent Protein |
MIC | Minimum Inhibitory Concentration |
K. aerogenes | Klebsiella aerogenes |
References
- Vargason, A.M.; Anselmo, A.C.; Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 2021, 5, 951–967. [Google Scholar] [CrossRef]
- Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med. 2019, 4, e10143. [Google Scholar] [CrossRef] [Green Version]
- Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; del Pilar Rodriguez-Torres, M.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 2018, 16, 71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 2016, 1, 10–29. [Google Scholar] [CrossRef] [PubMed]
- van der Meel, R.; Sulheim, E.; Shi, Y.; Kiessling, F.; Mulder, W.J.; Lammers, T. Smart cancer nanomedicine. Nat. Nanotechnol. 2019, 14, 1007–1017. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 2021, 20, 101–124. [Google Scholar] [CrossRef] [PubMed]
- Elsharkasy, O.M.; Nordin, J.Z.; Hagey, D.W.; de Jong, O.G.; Schiffelers, R.M.; Andaloussi, S.E.; Vader, P. Extracellular vesicles as drug delivery systems: Why and how? Adv. Drug Deliv. Rev. 2020, 159, 332–343. [Google Scholar] [CrossRef] [PubMed]
- Li, C.; Wang, J.; Wang, Y.; Gao, H.; Wei, G.; Huang, Y.; Yu, H.; Gan, Y.; Wang, Y.; Mei, L.; et al. Recent progress in drug delivery. Acta Pharm. Sin. B 2019, 9, 1145–1162. [Google Scholar] [CrossRef] [PubMed]
- Kalhapure, R.S.; Suleman, N.; Mocktar, C.; Seedat, N.; Govender, T. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J. Pharm. Sci. 2015, 104, 872–905. [Google Scholar] [CrossRef]
- Sandri, A.M.; Landersdorfer, C.B.; Jacob, J.; Boniatti, M.M.; Dalarosa, M.G.; Falci, D.R.; Behle, T.F.; Bordinhão, R.C.; Wang, J.; Forrest, A.; et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin. Infect. Dis. 2013, 57, 524–531. [Google Scholar] [CrossRef]
- Abdelraouf, K.; Braggs, K.H.; Yin, T.; Truong, L.D.; Hu, M.; Tam, V.H. Characterization of polymyxin B-induced nephrotoxicity: Implications for dosing regimen design. Antimicrob. Agents Chemother. 2012, 56, 4625–4629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khan, M.A.; Khan, A. Role of NKT cells during viral infection and the development of NKT cell-based nanovaccines. Vaccines 2021, 9, 949. [Google Scholar] [CrossRef] [PubMed]
- Bahadar, H.; Maqbool, F.; Niaz, K.; Abdollahi, M. Toxicity of nanoparticles and an overview of current experimental models. Iran. Biomed. J. 2016, 20, 1–11. [Google Scholar]
- Khan, M.A. Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the treatment of infectious diseases and tumors. Curr. Drug Targets 2021, 22, 770–778. [Google Scholar] [CrossRef]
- Drulis-Kawa, Z.; Dorotkiewicz-Jach, A. Liposomes as delivery systems for antibiotics. Int. J. Pharm. 2010, 387, 187–198. [Google Scholar] [CrossRef] [PubMed]
- Pierigè, F.; Serafini, S.; Rossi, L.; Magnani, M. Cell-based drug delivery. Adv. Drug Deliv. Rev. 2008, 60, 286–295. [Google Scholar] [CrossRef]
- Muzykantov, V.R. Drug delivery by red blood cells: Vascular carriers designed by mother nature. Expert Opin. Drug Deliv. 2010, 7, 403–427. [Google Scholar] [CrossRef] [Green Version]
- Villa, C.H.; Anselmo, A.C.; Mitragotri, S.; Muzykantov, V. Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv. Drug Deliv. Rev. 2016, 106, 88–103. [Google Scholar] [CrossRef] [Green Version]
- Zaitsev, S.; Kowalska, M.A.; Neyman, M.; Carnemolla, R.; Tliba, S.; Ding, B.S.; Stonestrom, A.; Spitzer, D.; Atkinson, J.P.; Poncz, M.; et al. Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis. Blood J. Am. Soc. Hematol. 2012, 119, 4779–4785. [Google Scholar] [CrossRef] [Green Version]
- Lorentz, K.M.; Kontos, S.; Diaceri, G.; Henry, H.; Hubbell, J.A. Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci. Adv. 2015, 1, e1500112. [Google Scholar] [CrossRef] [Green Version]
- Hu, C.M.J.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R.H.; Zhang, L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. USA 2011, 108, 10980–10985. [Google Scholar] [CrossRef] [PubMed]
- Himbert, S.; Blacker, M.J.; Kihm, A.; Pauli, Q.; Khondker, A.; Yang, K.; Sinjari, S.; Johnson, M.; Juhasz, J.; Wagner, C.; et al. Hybrid erythrocyte liposomes: Functionalized red blood cell membranes for molecule encapsulation. Adv. Biosyst. 2020, 4, 1900185. [Google Scholar] [CrossRef] [PubMed]
- Himbert, S.; Qadri, S.M.; Sheffield, W.P.; Schubert, P.; D’Alessandro, A.; Rheinstädter, M.C. Blood bank storage of red blood cells increases RBC cytoplasmic membrane order and bending rigidity. PLoS ONE 2021, 16, e0259267. [Google Scholar] [CrossRef] [PubMed]
- Himbert, S.; Alsop, R.J.; Rose, M.; Hertz, L.; Dhaliwal, A.; Moran-Mirabal, J.M.; Verschoor, C.P.; Bowdish, D.M.; Kaestner, L.; Wagner, C.; et al. The molecular structure of human red blood cell membranes from highly oriented, solid supported multi-lamellar membranes. Sci. Rep. 2017, 7, 39661. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.C.; Derick, L.H.; Palek, J. Visualization of the hexagonal lattice in the erythrocyte membrane skeleton. J. Cell Biol. 1987, 104, 527–536. [Google Scholar] [CrossRef] [Green Version]
- Singer, S.; Nicolson, G. The fluid mosaic model of the structure of cell membranes. Science 1972, 175, 720–731. [Google Scholar] [CrossRef]
- Mohandas, N.; Gallagher, P.G. Red cell membrane: Past, present, and future. Blood 2008, 112, 3939–3948. [Google Scholar] [CrossRef] [Green Version]
- Himbert, S.; Rheinstädter, M. Structural and mechanical properties of the red blood cell’s cytoplasmic membrane seen through the lens of biophysics. Front. Physiol. 2022, 13, 953257. [Google Scholar] [CrossRef]
- Van Meer, G.; Voelker, D.R.; Feigenson, G.W. Membrane lipids: Where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008, 9, 112–124. [Google Scholar] [CrossRef]
- Falck, E.; Patra, M.; Karttunen, M.; Hyvönen, M.T.; Vattulainen, I. Lessons of slicing membranes: Interplay of packing, free area, and lateral diffusion in phospholipid/cholesterol bilayers. Biophys. J. 2004, 87, 1076–1091. [Google Scholar] [CrossRef] [Green Version]
- Reisz, J.A.; Zheng, C.; D’Alessandro, A.; Nemkov, T. Untargeted and semi-targeted lipid analysis of biological samples using mass spectrometry-based metabolomics. In High-Throughput Metabolomics; Springer: Berlin/Heidelberg, Germany, 2019; pp. 121–135. [Google Scholar]
- Himbert, S.; D’Alessandro, A.; Qadri, S.M.; Majcher, M.J.; Hoare, T.; Sheffield, W.P.; Nagao, M.; Nagle, J.F.; Rheinstädter, M.C. The bending rigidity of the red blood cell cytoplasmic membrane. PLoS ONE 2022, 17, e0269619. [Google Scholar] [CrossRef] [PubMed]
- Dodge, J.T.; Phillips, G.B. Composition of phospholipids and of phospholipid fatty acids and aldehydes in human red cells. J. Lipid Res. 1967, 8, 667–675. [Google Scholar] [CrossRef] [PubMed]
- Almizraq, R.; Tchir, J.D.; Holovati, J.L.; Acker, J.P. Storage of red blood cells affects membrane composition, microvesiculation, and in vitro quality. Transfusion 2013, 53, 2258–2267. [Google Scholar] [CrossRef] [PubMed]
- Himbert, S.; Gastaldo, I.P.; Ahmed, R.; Pomier, K.M.; Cowbrough, B.; Jahagirdar, D.; Ros, S.; Juhasz, J.; Stöver, H.D.; Ortega, J.; et al. Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes. PLoS ONE 2022, 17, e0263671. [Google Scholar] [CrossRef] [PubMed]
- Fang, R.H.; Hu, C.M.J.; Zhang, L. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin. Biol. Ther. 2012, 12, 385–389. [Google Scholar] [CrossRef]
- Oldenborg, P.A.; Zheleznyak, A.; Fang, Y.F.; Lagenaur, C.F.; Gresham, H.D.; Lindberg, F.P. Role of CD47 as a marker of self on red blood cells. Science 2000, 288, 2051–2054. [Google Scholar] [CrossRef]
- Rodriguez, P.L.; Harada, T.; Christian, D.A.; Pantano, D.A.; Tsai, R.K.; Discher, D.E. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339, 971–975. [Google Scholar] [CrossRef] [Green Version]
- Dong, E.; Du, H.; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020, 20, 533–534. [Google Scholar] [CrossRef]
- Anfinrud, P.; Stadnytskyi, V.; Bax, C.E.; Bax, A. Visualizing speech-generated oral fluid droplets with laser light scattering. New Engl. J. Med. 2020, 382, 2061–2063. [Google Scholar] [CrossRef]
- Somsen, G.A.; van Rijn, C.; Kooij, S.; Bem, R.A.; Bonn, D. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet. Respir. Med. 2020, 8, 658–659. [Google Scholar] [CrossRef]
- Aiello, F.; Afflitto, G.G.; Mancino, R.; Li, J.P.O.; Cesareo, M.; Giannini, C.; Nucci, C. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: A systematic review. Eye 2020, 34, 1206–1211. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeo, C.; Kaushal, S.; Yeo, D. Enteric involvement of coronaviruses: Is faecal–oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol. Hepatol. 2020, 5, 335–337. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020, 181, 281–292. [Google Scholar] [CrossRef] [PubMed]
- Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269. [Google Scholar] [CrossRef] [Green Version]
- Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020, 367, 1260–1263. [Google Scholar] [CrossRef] [Green Version]
- Masters, P.S. The molecular biology of coronaviruses. Adv. Virus Res. 2006, 66, 193–292. [Google Scholar]
- Cai, Y.; Zhang, J.; Xiao, T.; Peng, H.; Sterling, S.M.; Walsh, R.M.; Rawson, S.; Rits-Volloch, S.; Chen, B. Distinct conformational states of SARS-CoV-2 spike protein. Science 2020, 369, 1586–1592. [Google Scholar] [CrossRef]
- Du, L.; He, Y.; Zhou, Y.; Liu, S.; Zheng, B.J.; Jiang, S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009, 7, 226–236. [Google Scholar] [CrossRef]
- Le, T.T.; Andreadakis, Z.; Kumar, A.; Roman, R.G.; Tollefsen, S.; Saville, M.; Mayhew, S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020, 19, 305–306. [Google Scholar] [CrossRef]
- Chung, Y.H.; Beiss, V.; Fiering, S.N.; Steinmetz, N.F. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano 2020, 14, 12522–12537. [Google Scholar] [CrossRef] [PubMed]
- Graham, B.S. Rapid COVID-19 vaccine development. Science 2020, 368, 945–946. [Google Scholar] [CrossRef] [PubMed]
- Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261. [Google Scholar] [CrossRef] [Green Version]
- Pan, D.C.; Myerson, J.W.; Brenner, J.S.; Patel, P.N.; Anselmo, A.C.; Mitragotri, S.; Muzykantov, V. Nanoparticle properties modulate their attachment and effect on carrier red blood cells. Sci. Rep. 2018, 8, 1615. [Google Scholar]
- Brenner, J.S.; Pan, D.C.; Myerson, J.W.; Marcos-Contreras, O.A.; Villa, C.H.; Patel, P.; Hekierski, H.; Chatterjee, S.; Tao, J.Q.; Parhiz, H.; et al. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat. Commun. 2018, 9, 2684. [Google Scholar] [CrossRef] [Green Version]
- Mueller, E.; Himbert, S.; Simpson, M.J.; Bleuel, M.; Rheinstadter, M.C.; Hoare, T. Cationic, anionic, and amphoteric dual pH/temperature-responsive degradable microgels via self-assembly of functionalized oligomeric precursor polymers. Macromolecules 2020, 54, 351–363. [Google Scholar] [CrossRef]
- Majcher, M.J.; McInnis, C.L.; Himbert, S.; Alsop, R.J.; Kinio, D.; Bleuel, M.; Rheinstädter, M.C.; Smeets, N.M.; Hoare, T. Photopolymerized starchstarch nanoparticle (SNP) network hydrogels. Carbohydr. Polym. 2020, 236, 115998. [Google Scholar] [CrossRef]
- Kravtzoff, R.; Colombat, P.; Desbois, I.; Linassier, C.; Muh, J.; Philip, T.; Blay, J.; Gardenbas, M.; Poumier-Gaschard, P.; Lamagnere, J.; et al. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur. J. Clin. Pharmacol. 1996, 51, 221–225. [Google Scholar] [CrossRef]
- Glassman, P.M.; Villa, C.H.; Ukidve, A.; Zhao, Z.; Smith, P.; Mitragotri, S.; Russell, A.J.; Brenner, J.S.; Muzykantov, V.R. Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. Pharmaceutics 2020, 12, 440. [Google Scholar] [CrossRef]
- Chiarantini, L.; Argnani, R.; Zucchini, S.; Stevanato, L.; Zabardi, P.; Grossi, M.P.; Magnani, M.; Manservigi, R. Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: Immunogenicity and protection in mice. Vaccine 1997, 15, 276–280. [Google Scholar] [CrossRef]
- Boberg, A.; Dominici, S.; Brave, A.; Hallermalm, K.; Hinkula, J.; Magnani, M.; Wahren, B. Immunization with HIV protease peptides linked to syngeneic erythrocytes. Infect. Agents Cancer 2007, 2, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grimm, A.J.; Kontos, S.; Diaceri, G.; Quaglia-Thermes, X.; Hubbell, J.A. Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. Sci. Rep. 2015, 5, 15907. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, H.L.; Brodsky, I.E.; Mangalmurti, N.S. The evolving erythrocyte: Red blood cells as modulators of innate immunity. J. Immunol. 2018, 201, 1343–1351. [Google Scholar] [CrossRef] [PubMed]
- Baum, J.; Ward, R.H.; Conway, D.J. Natural selection on the erythrocyte surface. Mol. Biol. Evol. 2002, 19, 223–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Minasyan, H. Phagocytosis and oxycytosis: Two arms of human innate immunity. Immunol. Res. 2018, 66, 271–280. [Google Scholar] [CrossRef] [PubMed]
- Ukidve, A.; Zhao, Z.; Fehnel, A.; Krishnan, V.; Pan, D.C.; Gao, Y.; Mandal, A.; Muzykantov, V.; Mitragotri, S. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. Proc. Natl. Acad. Sci. USA 2020, 117, 17727–17736. [Google Scholar] [CrossRef]
- Cheetham, P.S. Removal of Triton X-100 from aqueous solution using Amberlite XAD-2. Anal. Biochem. 1979, 92, 447–452. [Google Scholar] [CrossRef]
- Skar-Gislinge, N.; Johansen, N.T.; Høiberg-Nielsen, R.; Arleth, L. Comprehensive study of the self-assembly of phospholipid nanodiscs: What determines their shape and stoichiometry? Langmuir 2018, 34, 12569–12582. [Google Scholar] [CrossRef]
- Yang, J.; Wang, W.; Chen, Z.; Lu, S.; Yang, F.; Bi, Z.; Bao, L.; Mo, F.; Li, X.; Huang, Y.; et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020, 586, 572–577. [Google Scholar] [CrossRef]
- Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.Y.; et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020, 181, 894–904. [Google Scholar] [CrossRef]
- Krammer, F. SARS-CoV-2 vaccines in development. Nature 2020, 586, 516–527. [Google Scholar] [CrossRef] [PubMed]
- Petrovsky, N. Comparative safety of vaccine adjuvants: A summary of current evidence and future needs. Drug Saf. 2015, 38, 1059–1074. [Google Scholar] [CrossRef]
- Ventola, C.L. The antibiotic resistance crisis: Part 1: Causes and threats. Pharm. Ther. 2015, 40, 277. [Google Scholar]
- Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.; Wertheim, H.F.; Sumpradit, N.; Vlieghe, E.; Hara, G.L.; Gould, I.M.; Goossens, H.; et al. Antibiotic resistance—The need for global solutions. Lancet Infect. Dis. 2013, 13, 1057–1098. [Google Scholar] [CrossRef]
- Paterson, D.L. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control 2006, 34, S20–S28. [Google Scholar] [CrossRef] [PubMed]
- Zavascki, A.P.; Nation, R.L. Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B? Antimicrob. Agents Chemother. 2017, 61, e02319-16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yuan, Z.; Tam, V.H. Polymyxin B: A new strategy for multidrug-resistant Gram-negative organisms. Expert Opin. Investig. Drugs 2008, 17, 661–668. [Google Scholar] [CrossRef] [PubMed]
- Trimble, M.J.; Mlynárčik, P.; Kolář, M.; Hancock, R.E. Polymyxin: Alternative mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 2016, 6, a025288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rabanal, F.; Cajal, Y. Recent advances and perspectives in the design and development of polymyxins. Nat. Prod. Rep. 2017, 34, 886–908. [Google Scholar] [CrossRef]
- Zavascki, A.P.; Goldani, L.Z.; Li, J.; Nation, R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J. Antimicrob. Chemother. 2007, 60, 1206–1215. [Google Scholar] [CrossRef] [Green Version]
- Hemeg, H.A. Nanomaterials for alternative antibacterial therapy. Int. J. Nanomed. 2017, 12, 8211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brown, A.N.; Smith, K.; Samuels, T.A.; Lu, J.; Obare, S.O.; Scott, M.E. Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl. Environ. Microbiol. 2012, 78, 2768–2774. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shaker, M.A.; Shaaban, M.I. Formulation of carbapenems loaded gold nanoparticles to combat multi-antibiotic bacterial resistance: In vitro antibacterial study. Int. J. Pharm. 2017, 525, 71–84. [Google Scholar] [CrossRef] [PubMed]
- Alhajlan, M.; Alhariri, M.; Omri, A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob. Agents Chemother. 2013, 57, 2694–2704. [Google Scholar] [CrossRef] [PubMed]
- Omri, A.; Suntres, Z.E.; Shek, P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 2002, 64, 1407–1413. [Google Scholar] [CrossRef] [PubMed]
- Alipour, M.; Halwani, M.; Omri, A.; Suntres, Z.E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int. J. Pharm. 2008, 355, 293–298. [Google Scholar] [CrossRef]
- McAllister, S.; Alpar, H.; Brown, M. Antimicrobial properties of liposomal polymyxin B. J. Antimicrob. Chemother. 1999, 43, 203–210. [Google Scholar] [CrossRef] [Green Version]
- Krivić, H.; Himbert, S.; Sun, R.; Feigis, M.; Rheinstädter, M.C. Erythro-PmBs: A Selective Polymyxin B Delivery System Using Antibody-Conjugated Hybrid Erythrocyte Liposomes. ACS Infect. Dis. 2022, 8, 2059–2072. [Google Scholar] [CrossRef] [PubMed]
- Khondker, A.; Alsop, R.J.; Dhaliwal, A.; Saem, S.; Moran-Mirabal, J.M.; Rheinstädter, M.C. Membrane cholesterol reduces polymyxin B nephrotoxicity in renal membrane analogs. Biophys. J. 2017, 113, 2016–2028. [Google Scholar] [CrossRef] [Green Version]
- Clausell, A.; Garcia-Subirats, M.; Pujol, M.; Busquets, M.A.; Rabanal, F.; Cajal, Y. Gram-negative outer and inner membrane models: Insertion of cyclic cationic lipopeptides. J. Phys. Chem. B 2007, 111, 551–563. [Google Scholar] [CrossRef]
- Velino, C.; Carella, F.; Adamiano, A.; Sanguinetti, M.; Vitali, A.; Catalucci, D.; Bugli, F.; Iafisco, M. Nanomedicine approaches for the pulmonary treatment of cystic fibrosis. Front. Bioeng. Biotechnol. 2019, 7, 406. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ong, H.X.; Traini, D.; Cipolla, D.; Gonda, I.; Bebawy, M.; Agus, H.; Young, P.M. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res. 2012, 29, 3335–3346. [Google Scholar] [CrossRef] [PubMed]
- Meers, P.; Neville, M.; Malinin, V.; Scotto, A.; Sardaryan, G.; Kurumunda, R.; Mackinson, C.; James, G.; Fisher, S.; Perkins, W. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 2008, 61, 859–868. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Krivić, H.; Himbert, S.; Rheinstädter, M.C. Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases. Membranes 2022, 12, 1226. https://doi.org/10.3390/membranes12121226
Krivić H, Himbert S, Rheinstädter MC. Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases. Membranes. 2022; 12(12):1226. https://doi.org/10.3390/membranes12121226
Chicago/Turabian StyleKrivić, Hannah, Sebastian Himbert, and Maikel C. Rheinstädter. 2022. "Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases" Membranes 12, no. 12: 1226. https://doi.org/10.3390/membranes12121226